Last reviewed · How we verify
NCT05001113
Surgery for Masaoka-Koga I-II Thymoma
NA trial testing the subxiphoid approach thoracoscopic thymectomy in Thymoma in 101 participants. Completed in 17 August 2022.
15 February 2022
Quick facts
| Lead sponsor | Shanghai Zhongshan Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 101 |
| Start date | 15 August 2021 |
| Primary completion | 15 February 2022 |
| Estimated completion | 17 August 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- the subxiphoid approach thoracoscopic thymectomy
- the lateral intercostal approach thoracoscopic thymectomy
Conditions studied
- Thymoma — all drugs for Thymoma →
- Masaoka Stage I — all drugs for Masaoka Stage I →
- Masaoka Stage II — all drugs for Masaoka Stage II →
Sponsor
Shanghai Zhongshan Hospital
Who can join
Adults 18 to 75, any sex, with Thymoma or Masaoka Stage I. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study was to evaluate the safety and perioperative outcomes of the subxiphoid approach versus the lateral intercostal approach thoracoscopic thymectomy for Masaoka-Koga I-II thymoma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05001113
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Thymoma
Currently open trials in the same condition.
- NCT06730308 — Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma · Phase 2 · recruiting
- NCT06692062 — Hypofractionated Radiotherapy for Thymic Epithelial Tumors · NA · recruiting
- NCT06029621 — Robot-assisted vs VATS for Thymoma · NA · recruiting
- NCT06301945 — Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors · recruiting
- NCT05682742 — Clinical Investigation of the da Vinci Surgical System · NA · active not recruiting
Other Shanghai Zhongshan Hospital trials
Trials by the same sponsor.
- NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
- NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
- NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
- NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
- NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05001113 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
- Last refreshed: 19 September 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05001113.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing